Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)

Market Cap	56.63B
Revenue (ttm)	182.56B
Net Income (ttm)	-7.52B
Shares Out	15.33M
EPS (ttm)	-501.22
PE Ratio	n/a
Forward PE	n/a
Dividend	75.00 (2.03%)
Ex-Dividend Date	Dec 27, 2024

Volume	21,987
Average Volume	22,812
Open	3,630.00
Previous Close	3,660.00
Day's Range	3,630.00 - 3,705.00
52-Week Range	3,070.00 - 6,090.00
Beta	0.70
RSI	62.41
Earnings Date	n/a

About Korea Arlico Pharm

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients. The company provides products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. w...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 112
• Stock Exchange: KOSDAQ
• Ticker Symbol: 260660

Financial Performance

In 2023, Korea Arlico Pharm's revenue was 187.15 billion, an increase of 11.58% compared to the previous year's 167.74 billion. Earnings were 3.06 billion, a decrease of -61.90%.